COLUMBIA, Md.–(BUSINESS WIRE)– Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that it is evaluating the establishment of an international, ex-U.S. subsidiary in recognition of its expanding research and commercial business operations. The Company is currently evaluating different locations, including United Kingdom, Singapore and Switzerland.
